# OnCo record nct04302025 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04302025/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04302025", "NCT04302025" ;
  schema:name "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)"@en ;
  schema:alternateName "NAUTIKA1"@en ;
  schema:description "A phase 2 trial of Alectinib, Entrectinib, Vemurafenib in non-small-cell lung cancer and small-cell lung cancer, run by Genentech, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04302025/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04302025> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-11-06" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> .